Three IPOs each raised less than $50 million during the shortened holiday week. Two biotechs and one regional bank all priced below their proposed ranges, but finished the week above the IPO price. Last week's IPO activity continues what we saw in the second...read more
GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, raised $15 million by offering 1.5 million shares at $10, below the expected $15 offer price. GlobeImmune plans to list on the NASDAQ under the symbol GBIM. Aegis...read more
GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, lowered the proposed deal size for its upcoming IPO on Monday. The Louisville, CO-based company now plans to raise $15 million by offering 1.0 million shares at $15...read more
US IPO Pricing Recap: Three small and discounted deals price before the holiday
Three IPOs each raised less than $50 million during the shortened holiday week. Two biotechs and one regional bank all priced below their proposed ranges, but finished the week above the IPO price. Last week's IPO activity continues what we saw in the second...read more
GlobeImmune prices IPO at $10, below the range
GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, raised $15 million by offering 1.5 million shares at $10, below the expected $15 offer price. GlobeImmune plans to list on the NASDAQ under the symbol GBIM. Aegis...read more
GlobeImmune decreases shares offered, drops expected IPO price to $15
GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, lowered the proposed deal size for its upcoming IPO on Monday. The Louisville, CO-based company now plans to raise $15 million by offering 1.0 million shares at $15...read more
7 US IPOs planned for the week of Jun 30
The following IPOs are expected to price this week: Ambrx (AMBX), a biotech developing bio-conjugates to treat solid tumors and other diseases, plans to raise $70...read more